A61P 7/00
Drugs for disorders of the blood or the extracellular fluid
A61P7/00 (Drugs for disorders of the blood or the extracellular fluid) appears on 26,481 US grants and 37,325 published applications in this corpus.
Search patents in A61P- Granted patents
- 26,481
- Published applications
- 37,325
- Assignees
- 8,655
- Inventors
- 54,039
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 21 | 0 |
| 1977 | 25 | 0 |
| 1978 | 48 | 0 |
| 1979 | 36 | 0 |
| 1980 | 51 | 0 |
| 1981 | 66 | 0 |
| 1982 | 71 | 0 |
| 1983 | 60 | 0 |
| 1984 | 89 | 0 |
| 1985 | 122 | 0 |
| 1986 | 124 | 0 |
| 1987 | 137 | 0 |
| 1988 | 141 | 0 |
| 1989 | 168 | 0 |
| 1990 | 146 | 0 |
| 1991 | 151 | 0 |
| 1992 | 173 | 0 |
| 1993 | 113 | 0 |
| 1994 | 152 | 0 |
| 1995 | 192 | 0 |
| 1996 | 221 | 0 |
| 1997 | 315 | 0 |
| 1998 | 415 | 0 |
| 1999 | 406 | 0 |
| 2000 | 385 | 0 |
| 2001 | 454 | 146 |
| 2002 | 557 | 799 |
| 2003 | 543 | 1315 |
| 2004 | 485 | 1588 |
| 2005 | 493 | 1585 |
| 2006 | 684 | 1636 |
| 2007 | 662 | 1663 |
| 2008 | 752 | 1902 |
| 2009 | 834 | 2170 |
| 2010 | 1200 | 2454 |
| 2011 | 1246 | 2317 |
| 2012 | 1468 | 2424 |
| 2013 | 1667 | 1884 |
| 2014 | 1655 | 1945 |
| 2015 | 1460 | 1749 |
| 2016 | 1300 | 1755 |
| 2017 | 1288 | 1525 |
| 2018 | 1076 | 1443 |
| 2019 | 1050 | 1327 |
| 2020 | 883 | 1157 |
| 2021 | 752 | 1013 |
| 2022 | 580 | 873 |
| 2023 | 472 | 840 |
| 2024 | 432 | 747 |
| 2025 | 446 | 649 |
| 2026 | 214 | 419 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Methods for treating drug and vaccine induced immune thrombocytopenia by administering specific compounds6 Oct 2026US 12,751,954 B2Principia Biopharma Inc.
- Methods for reducing skin porphyrin content and inciddence of acnes, or increasing ferritin content within intestinal cells by using queen plum extract6 Oct 2026US 12,751,987 B2Tci Co., Ltd.
- Methods of culturing quiescent hematopoietic stem cells and treatment methods6 Oct 2026US 12,753,389 B2Icahn School of Medicine at Mount Sinai
- Compositions and methods for the treatment of hemophilia6 Oct 2026US 12,753,418 B2Poseida Therapeutics, Inc.
- Treating vasculature related diseases or disorders using nanoparticles29 Sep 2026US 12,746,212 B2The Regents of the University of California
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Treatment of clonal hematopoietic disorders using kinase inhibitors8 Oct 2026US 2026/0306462 A1
- Use of milvexian in the treatment and prevention of thrombotic conditions in patients with atrial fibrilation8 Oct 2026US 2026/0306492 A1Bristol-Myers Squibb Company
- (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease8 Oct 2026US 2026/0306503 A1Global Blood Therapeutics, Inc.
- Factor xi a2 domain-binding antibodies and methods of use thereof8 Oct 2026US 2026/0308276 A1Regeneron Pharmaceuticals, Inc.
Most cited
By later US patents
- Drug releasing anastomosis devices and methods for treating anastomotic sites1,779US 7,108,701 B2Ethicon, Inc. · 2006
- Drug releasing biodegradable fiber implant1,662US 6,596,296 B1Board of Regents, The University of Texas System · 2003
- Plasma protein matrices and methods for their preparation1,406US 7,009,039 B2ProChon Biotech Ltd. · 2006
- Nanostructure-enhanced platelet binding and hemostatic structures1,405US 8,319,002 B2Nanosys, Inc. · 2012
- Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue1,214US 6,458,147 B1NeoMend, Inc. · 2002